In addition, more profound effects by dual pharmacological inhibition (Fig. 6) than VEGF neutralization plus EC-specific PDGFR-β knockout (Fig. 7) in our animal studies implicate that pericyte eradication by PDGF inhibition may exert additional benefits in GBM therapy. The gene discussed is PDGFRB; the disease is glioblastoma.